Exciting News from OKYO Pharma!
Thrilled to announce Robert J. Dempsey as our new CEO, effective immediately!
With 20+ years in ophthalmology, Robert led Shire's Global Ophthalmology & the landmark XIIDRA® deal, which was one of only three ophthalmology deals in the past twenty years with more than $1 billion upfront. The sale of Xiidra® to Novartis in 2019 included $3.4 billion upfront and up to an additional $1.9 billion in potential milestone payments, which was acquired 4 years later by Bausch + Lomb.
His expertise will accelerate our lead asset urcosimod for neuropathic corneal pain (NCP) & ocular inflammation.
Welcome, Robert—we're poised for growth.
#OKYOPharma #Biotech #Ophthalmology #Optometry #Leadership #Innovation $OKYO
https://t.co/vaCv97lkIv